Master of Science (M.S.)
Degree Granting Department
Vijaykumar Sutariya, Ph.D.
Sheeba Varghese Gupta, M. Pharm, Ph.D.
Pranav Patel, Ph.D.
Age-Related Macular Degeneration, Anti-VEGF, MPEG-PCL, Sunitinib, sustained release
Age-related Macular Degeneration, or AMD will be responsible for the vision impairment of more than 5 million late-aged adults in the next 30 years. Current treatment options include frequent intravitreal injections which report high levels of pain resulting in a low patient compliance. However, there are methods of drug delivery that can decrease the amount of intravitreal injections by sustaining drug release. Polymeric micelles, specifically MPEG-PCL have reported superb biocompatibility and more efficient ways of delivering anti-VEGF drugs such as Sunitinib to the posterior segment of the eye. In this study, the novel micellar formulation exhibited an average DLS particle size of 132.7 nm with a ZP of -0.159 mV. TEM imaging further confirmed the nanoscopic size of the micelles with sizes ranging from 86.76 to 114.51 nm. In addition to their miniscule size, the SM-MPEG-PCL formulation showed minimal cytotoxicity onto ARPE-19 human retinal pigment epithelial cell line reporting a % viability of more than 88% for all concentrations at time intervals of 24 and 48h. The SM-MPEG-PCL micelles also exhibited exceptional performance during an anti-VEGF ELISA that decreased the overall VEGF protein expression in the cells across a 24-72 hour period. Furthermore, it can be concluded that this type of polymeric vehicle is a promising solution to symptoms caused by AMD and improving the management of those suffering from AMD.
Scholar Commons Citation
Streets, Jarriaun D., "Sunitinib-loaded MPEG-PCL Micelles for the Treatment of Age-Related Macular Degeneration" (2020). Graduate Theses and Dissertations.